Synaps Dx recently presented data on potential cost savings with DISCERN™ at the 2022 International Conference on Aging Diseases and Elderly Care (ICADEC).  The data presented demonstrated that the improved accuracy with DISCERN™ was cost saving for a Medicare Advantage plan, based on the currently available diagnostic and treatment options.  The savings from this model assumed that clinicians would initially add DISCERN™ to the other battery of cognitive, imaging, and CSF tests that are in the current diagnostic pathway.  Over time, as clinicians became more comfortable with the DISCERN™ test, the cost savings would increase dramatically as reliance on the more expensive imaging and CSF tests was reduced.